Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism. 1987

C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman

Susceptibility to multiple sclerosis (MS) has been linked to the immunoglobulin G (Gm) markers as well as HLA-DR genes. We have used a genomic Ig gamma 1 probe which detects polymorphisms in the gamma 1, gamma 2, gamma 3 and pseudogamma genes to identify restriction fragment length polymorphisms associated with MS. A negative association was found between a 5.9-kilobase (kb) Bst EII gamma 3 fragment and MS. Southern blot analysis of genomic DNA revealed the presence of this fragment in 84 of 140 (60.0%) controls, but in only 17 of 59 (28.8%) MS patients. The frequency of the fragment in 47 myasthenia gravis and 16 Graves' disease patients was similar to that in controls, 60.0 and 62.5%, respectively.

UI MeSH Term Description Entries
D007126 Immunoglobulin Allotypes Allelic variants of the immunoglobulin light chains (IMMUNOGLOBULIN LIGHT CHAINS) or heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) encoded by ALLELES of IMMUNOGLOBULIN GENES. Allotypes, Immunoglobulin,Allotypic Antibodies,Antibodies, Allotypic,Ig Allotypes,Allotype, Ig,Allotype, Immunoglobulin,Allotypes, Ig,Allotypic Antibody,Antibody, Allotypic,Ig Allotype,Immunoglobulin Allotype
D007142 Immunoglobulin gamma-Chains Heavy chains of IMMUNOGLOBULIN G having a molecular weight of approximately 51 kDa. They contain about 450 amino acid residues arranged in four domains and an oligosaccharide component covalently bound to the Fc fragment constant region. The gamma heavy chain subclasses (for example, gamma 1, gamma 2a, and gamma 2b) of the IMMUNOGLOBULIN G isotype subclasses (IgG1, IgG2A, and IgG2B) resemble each other more closely than the heavy chains of the other IMMUNOGLOBULIN ISOTYPES. Immunoglobulins, gamma-Chain,Immunoglobulin gamma-Chain,gamma Immunoglobulin Heavy Chain,gamma Immunoglobulin Heavy Chains,gamma-1-Immunoglobulin Heavy Chain,gamma-2a-Immunoglobulin Heavy Chain,gamma-2b-Immunoglobulin Heavy Chain,gamma-Chain Immunoglobulins,Heavy Chain, gamma-1-Immunoglobulin,Heavy Chain, gamma-2a-Immunoglobulin,Heavy Chain, gamma-2b-Immunoglobulin,Immunoglobulin gamma Chain,Immunoglobulin gamma Chains,Immunoglobulins, gamma Chain,gamma 1 Immunoglobulin Heavy Chain,gamma 2a Immunoglobulin Heavy Chain,gamma 2b Immunoglobulin Heavy Chain,gamma Chain Immunoglobulins,gamma-Chain, Immunoglobulin,gamma-Chains, Immunoglobulin
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D008040 Genetic Linkage The co-inheritance of two or more non-allelic GENES due to their being located more or less closely on the same CHROMOSOME. Genetic Linkage Analysis,Linkage, Genetic,Analyses, Genetic Linkage,Analysis, Genetic Linkage,Genetic Linkage Analyses,Linkage Analyses, Genetic,Linkage Analysis, Genetic
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
June 1986, Human genetics,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
July 1991, The Journal of clinical investigation,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
January 1993, Immunogenetics,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
January 2002, Methods in molecular biology (Clifton, N.J.),
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
January 1990, Experimental and clinical immunogenetics,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
July 1986, The Journal of experimental medicine,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
July 1987, British journal of cancer,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
May 2001, Current protocols in human genetics,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
November 1983, Proceedings of the National Academy of Sciences of the United States of America,
C N Gaiser, and M J Johnson, and G de Lange, and L Rassenti, and L L Cavalli-Sforza, and L Steinman
April 2001, Genome,
Copied contents to your clipboard!